How India Exports Posaconazole to the World

In the United States, posaconazole is marketed under the brand name Noxafil. The FDA approved Noxafil oral suspension (NDA #022003) on September 15, 2006, and the injection formulation (NDA #205596) on March 13, 2014. Additionally, on June 17, 2021, the FDA approved Noxafil for the treatment of invasive aspergillosis in adults and pediatric patients aged 13 years and older, granting orphan drug exclusivity until June 17, 2028.

The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for posaconazole, indicating the presence of generic versions in the market. However, the dominance of AET Laboratories Private Limited in Indian exports suggests that a limited number of Indian manufacturers are supplying posaconazole to the U.S., potentially due to stringent regulatory requirements and market dynamics.

The European Medicines Agency (EMA) granted marketing authorization for Noxafil (posaconazole) on October 25, 2005, for treating various invasive fungal infections. Subsequently, on July 25, 2019, the EMA approved Posaconazole Accord, a generic version, for similar indications. (ema.europa.eu)

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval and regulation of medicinal products, including posaconazole. Manufacturers exporting to the EU and UK must comply with Good Manufacturing Practice (GMP) standards as outlined by the EMA and MHRA, ensuring product quality and safety.

Posaconazole is included in the World Health Organization's Model List of Essential Medicines, underscoring its importance in treating serious fungal infections. The drug is also listed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), reflecting its global acceptance and standardized quality parameters.

In India, posaconazole is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for posaconazole, allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with regulatory standards and to monitor the export of pharmaceutical products.

The primary patents for posaconazole have expired, leading to increased generic competition globally. However, specific formulations or new indications may still be under patent protection, granting exclusivity periods in certain markets. For instance, the FDA granted orphan drug exclusivity to Noxafil for the treatment of invasive aspergillosis until June 17, 2028.

In January 2026, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending an extension of the indication for Noxafil gastro-resistant tablets to include treatment of invasive aspergillosis in adults and pediatric patients from 2 years of age weighing more than 40 kg. (ema.europa.eu)

In December 2021, the FDA granted orphan drug designation to posaconazole for the treatment of mucormycosis, highlighting its potential in addressing rare fungal infections.

These developments reflect the evolving regulatory landscape and the ongoing efforts to expand the therapeutic applications of posaconazole.

Posaconazole, an antifungal agent, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. China controls approximately 70–80% of the global KSM supply, making it a dominant player in this sector. This dependency poses a significant risk, as any disruption in Chinese KSM production can directly impact the availability and cost of Posaconazole APIs.

Recent events have highlighted this vulnerability. In February 2026, the closure of the Strait of Hormuz disrupted the supply of raw materials to Asia's petrochemical industry, leading to production cutbacks and force majeure declarations. Such geopolitical tensions can exacerbate the fragility of supply chains dependent on single-country sourcing for critical raw materials.

Our proprietary trade data indicates a high supplier concentration in the export of Posaconazole from India. The top five exporters account for 96.0% of the total export value, with AET Laboratories Private Limited alone contributing 91.9%. This concentration poses a significant single-source risk; any operational or regulatory issues affecting AET Laboratories could severely disrupt the global supply of Posaconazole.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic manufacturing of critical APIs and reduce reliance on imports. As of November 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules used in common antibiotics. While this initiative is a positive step, its impact on diversifying Posaconazole suppliers remains to be seen.

Geopolitical tensions have recently intensified, notably with the closure of the Strait of Hormuz in February 2026 following attacks on Iran by the U.S. and Israel. This disruption has affected the supply of raw materials to Asia's petrochemical industry, leading to production cutbacks. Additionally, the Red Sea and the Strait of Hormuz have become hotspots for shipping threats, further complicating logistics for pharmaceutical exports.

While there have been no specific FDA or EMA shortage alerts for Posaconazole as of March 2026, the potential for such disruptions remains high. The FDA has acknowledged the broader issue of supply chain vulnerabilities and is actively monitoring the situation.

• Diversify Supplier Base: Encourage the development of additional manufacturing facilities for Posaconazole to reduce reliance on a single exporter.

• Strengthen Domestic KSM Production: Invest in domestic production of Key Starting Materials to decrease dependency on Chinese imports.

• Enhance Supply Chain Transparency: Implement robust tracking systems to monitor the flow of raw materials and finished products, enabling quicker responses to disruptions.

• Develop Contingency Plans: Establish alternative shipping routes and logistics strategies to mitigate the impact of geopolitical tensions on transportation.

• Engage in Policy Advocacy: Collaborate with industry associations and government bodies to advocate for policies that support supply chain resilience and reduce import dependencies.

RISK_LEVEL: HIGH